openPR Logo
Press release

Spinal Muscular Atrophy Pipeline Insight 2024, Therapies, Treatment and Companies: Analysis of Drugs, MOA, ROA, and Clinical Trials Results by DelveInsight

02-05-2024 12:45 PM CET | Health & Medicine

Press release from: DelveInsight Business Research

Spinal Muscular Atrophy Pipeline

Spinal Muscular Atrophy Pipeline

(Albany, USA) Spinal Muscular Atrophy pipeline constitutes 10+ key companies continuously working towards developing 10+ Spinal Muscular Atrophy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Spinal Muscular Atrophy Pipeline Insight, 2024″ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Spinal Muscular Atrophy Market.
The Spinal Muscular Atrophy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

To know more in detail about Spinal Muscular Atrophy pipeline report offerings, click here: https://www.delveinsight.com/report-store/spinal-muscular-atrophy-sma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Spinal Muscular Atrophy Overview
Spinal Muscular Atrophy (SMA) is a genetic neuromuscular disorder that affects the motor neurons in the spinal cord, leading to progressive muscle weakness and atrophy. It is caused by a deficiency in the survival motor neuron (SMN) protein due to mutations in the SMN1 gene. Spinal Muscular Atrophy is classified into different types based on age of onset and severity, with type 1 being the most severe and typically presenting in infancy.
The condition results in difficulty with basic motor functions such as crawling, sitting, and walking, and can lead to respiratory and swallowing difficulties in more severe cases. While there is currently no cure for Spinal Muscular Atrophy, advances in medical treatment, including gene therapy and medication such as nusinersen, have shown promising results in slowing disease progression and improving quality of life for those affected. Early diagnosis and comprehensive care are crucial to managing the condition effectively.

Some of the key takeaways from the Spinal Muscular Atrophy Pipeline Report:
• Companies across the globe are diligently working toward developing novel Spinal Muscular Atrophy treatment therapies with a considerable amount of success over the years. Spinal Muscular Atrophy Key players such as - Scholar Rock, Biogen, Astellas Pharma, Alcyone Therapeutics, AndroScience Corporation, Hanugen Theraputics, Voyager Therapeutics, Genethon, Astellas Pharma, Hoffmann-La Roche, and others, are developing therapies for the Spinal Muscular Atrophy treatment
• Spinal Muscular Atrophy emerging therapies such as - ACTX-401, Apitegromab, and others are expected to have a significant impact on the Spinal Muscular Atrophy market in the coming years.
• On July 2023, Novartis Pharmaceuticals announced an open-label, single arm, multi-centre study to evaluate the safety, tolerability and efficacy of IV OAV101 in SMA participants. The study will enroll participant's ≤ 24 months that weigh ≤ 17 kg. Participants will receive a single administration of IV OAV101 at the approved dose of 1.1e14 vg/kg.
• On May 2023, Biogen announced a study on Spinal Muscular Atrophy. The primary objective of the study is to describe the natural history and utilization of disease modifying therapy (DMT) among adult Chinese participants with SMA linked to chromosome 5q (5q-SMA).

To know in detail about the Spinal Muscular Atrophy clinical trials and recent FDA approvals for Spinal Muscular Atrophy drugs, click here: https://www.delveinsight.com/sample-request/spinal-muscular-atrophy-sma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Spinal Muscular Atrophy Pipeline Therapeutics Assessment
• Spinal Muscular Atrophy Assessment by Product Type
• Spinal Muscular Atrophy By Stage and Product Type
• Spinal Muscular Atrophy Assessment by Route of Administration
• Spinal Muscular Atrophy By Stage and Route of Administration
• Spinal Muscular Atrophy Assessment by Molecule Type
• Spinal Muscular Atrophy by Stage and Molecule Type

DelveInsight's Spinal Muscular Atrophy Report covers around 10+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Emerging Spinal Muscular Atrophy Drugs Under Different Phases of Clinical Development Include:
• ACTX-401: Novartis
• Apitegromab: Scholar Rock
• GYM329: Roche
• And Many Others

Get a Free Sample PDF Report to know more about Spinal Muscular Atrophy Pipeline Assessment: https://www.delveinsight.com/report-store/spinal-muscular-atrophy-sma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Spinal Muscular Atrophy Pipeline Analysis:
The Spinal Muscular Atrophy pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the Spinal Muscular Atrophy treatment with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Spinal Muscular Atrophy Treatment.
• Spinal Muscular Atrophy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Spinal Muscular Atrophy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Spinal Muscular Atrophy market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Spinal Muscular Atrophy product details are provided in the report. Download the Spinal Muscular Atrophy pipeline report to learn more about the emerging Spinal Muscular Atrophy therapies: https://www.delveinsight.com/sample-request/spinal-muscular-atrophy-sma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Scope of Spinal Muscular Atrophy Pipeline Drug Insight
• Coverage: Global
• Key Spinal Muscular Atrophy Companies: Acurastem, Everfront Biotech Co., Ltd, Eledon Pharmaceuticals, AL-S Pharma, Novartis, Annexon Biosceinces, MediciNova, Treeway, Biogen, and others
• Key Spinal Muscular Atrophy Therapies: AS-202, HK001, Tegoprubart, AP-101, BLZ945, ANX005, MN-166, TW001, BIIB067, and others
• Spinal Muscular Atrophy Therapeutic Assessment: Spinal Muscular Atrophy current marketed and Spinal Muscular Atrophy emerging therapies
• Spinal Muscular Atrophy Market Dynamics: Spinal Muscular Atrophy market drivers and Spinal Muscular Atrophy market barriers

Table of Contents
1 Spinal Muscular Atrophy Report Introduction
2 Spinal Muscular Atrophy Executive Summary
3 Spinal Muscular Atrophy Overview
4 Spinal Muscular Atrophy- Analytical Perspective In-depth Commercial Assessment
5 Spinal Muscular Atrophy Pipeline Therapeutics
6 Spinal Muscular Atrophy Late Stage Products (Phase II/III)
7 Spinal Muscular Atrophy Mid Stage Products (Phase II)
8 Spinal Muscular Atrophy Early Stage Products (Phase I)
9 Spinal Muscular Atrophy Preclinical Stage Products
10 Spinal Muscular Atrophy Therapeutics Assessment
11 Spinal Muscular Atrophy Inactive Products
12 Company-University Collaborations (Licensing/Partnering) Analysis
13 Spinal Muscular Atrophy Key Companies
14 Spinal Muscular Atrophy Key Products
15 Spinal Muscular Atrophy Unmet Needs
16 Spinal Muscular Atrophy Market Drivers and Barriers
17 Spinal Muscular Atrophy Future Perspectives and Conclusion
18 Spinal Muscular Atrophy Analyst Views
19 Appendix
20 About DelveInsight

Trending Report:
• Hiatal Hernia Market: https://www.delveinsight.com/report-store/hiatal-hernia-market
• Lhon Market: https://www.delveinsight.com/report-store/lebers-hereditary-optic-neuropathy-lhon-market
• Reactive Arthritis Market: https://www.delveinsight.com/report-store/reactive-arthritis-market
• Vascular Dementia Market: https://www.delveinsight.com/report-store/vascular-dementia-market
• Acquired Hemophilia A Pipeline: https://www.delveinsight.com/report-store/acquired-hemophilia-a-pipeline-insight
• Acute Gout Flare Market: https://www.delveinsight.com/report-store/acute-gout-flare-market
• Adrenal Insufficiency Market: https://www.delveinsight.com/report-store/adrenal-insufficiency-market
• Alkaptonuria Market: https://www.delveinsight.com/report-store/alkaptonuria-market
• Bronchopulmonary Dysplasia Market: https://www.delveinsight.com/report-store/bronchopulmonary-dysplasia-market
• Central Serous Chorioretinopathy Market: https://www.delveinsight.com/report-store/central-serous-chorioretinopathy-market
• Chronic Idiopathic Urticaria Market: https://www.delveinsight.com/report-store/chronic-idiopathic-urticaria-market
• Contusion Market: https://www.delveinsight.com/report-store/contusion-market
• Heavy Metal Poisoning Markets: https://www.delveinsight.com/report-store/heavy-metal-poisoning-market
• Microsatellite Stable Colorectal Cancer Market: https://www.delveinsight.com/report-store/microsatellite-stable-colorectal-cancer-market
• Phosphoglucomutase Pgm 1 Deficiency Market: https://www.delveinsight.com/report-store/phosphoglucomutase-pgm-1-deficiency-market
• Polypoidal Choroidal Vasculopathy Market: https://www.delveinsight.com/report-store/polypoidal-choroidal-vasculopathy-market
• Progressive Familial Intrahepatic Cholestasis Market: https://www.delveinsight.com/report-store/progressive-familial-intrahepatic-cholestasis-pfic-market
• Pulmonary Hypertension Associated With Interstitial Lung Disease Market: https://www.delveinsight.com/report-store/pulmonary-hypertension-associated-with-interstitial-lung-disease-ph-ild-market
• Upper Limb Hypertonia Market: https://www.delveinsight.com/report-store/upper-limb-hypertonia-market
• Vestibular Schwannoma Market: https://www.delveinsight.com/report-store/vestibular-schwannoma-market
• Advanced Hepatocellular Carcinoma With Cpb Liver Cirrhosis Market: https://www.delveinsight.com/report-store/advanced-hepatocellular-carcinoma-with-cpb-liver-cirrhosis-market-insight
• Aids Related Kaposi's Sarcoma Market: https://www.delveinsight.com/report-store/aids-related-kaposis-sarcoma-market
• Ankylosing Spondylitis Bekhterevs Disease Market: https://www.delveinsight.com/report-store/ankylosing-spondylitis-as-market
• Atypical Hemolytic Uremic Syndrome Ahus Market: https://www.delveinsight.com/report-store/atypical-hemolytic-uremic-syndrome-ahus-market
• Apraxia Market: https://www.delveinsight.com/report-store/apraxia-market
• Antiphospholipid Syndrome Aps Market: https://www.delveinsight.com/report-store/antiphospholipid-syndrome-aps-market
• Hallux Valgus Market: https://www.delveinsight.com/report-store/hallux-valgus-market
• Interbody Cages Market: https://www.delveinsight.com/report-store/interbody-cages-market
• Kidney Transplant Rejection Market: https://www.delveinsight.com/report-store/kidney-transplant-rejection-market
• Nmibc Market: https://www.delveinsight.com/report-store/non-muscle-invasive-bladder-cancer-market
• T-cell-prolymphocytic Leukemia Market: https://www.delveinsight.com/report-store/t-cell-prolymphocytic-leukemia-market
• Adult Onset Still Disease Market: https://www.delveinsight.com/report-store/adult-onset-still-disease-market
• Biliary Tract Cancer Market: https://www.delveinsight.com/report-store/biliary-tract-cancers-btcs-market
• Triple Negative Breast Cancer Market: https://www.delveinsight.com/report-store/triple-negative-breast-cancer-tnbc-market
• Ventricular Dysfunction Market: https://www.delveinsight.com/report-store/ventricular-dysfunction-market
• Diffuse Cutaneous Systemic Sclerosis Market: https://www.delveinsight.com/report-store/diffuse-cutaneous-systemic-sclerosis-dcssc-market
• Pemphigus Vulgaris Market: https://www.delveinsight.com/report-store/pemphigus-vulgaris-market
• Helicobacter Pylori Infections Market: https://www.delveinsight.com/report-store/helicobacter-pylori-h-pylori-infection-market
• Alzheimer Disease Market: https://www.delveinsight.com/report-store/alzheimers-disease-ad-market
• Anaphylaxis Market: https://www.delveinsight.com/report-store/anaphylaxis-market
• Nsclc Market: https://www.delveinsight.com/report-store/non-small-cell-lung-cancer-nsclc-market
• Blood Gas And Electrolyte Analyzers Market: https://www.delveinsight.com/report-store/blood-gas-and-electrolyte-analyzers-market
• Central Venous Catheters Market: https://www.delveinsight.com/report-store/central-venous-catheters-market
• Acral Lentiginous Melanoma Market: https://www.delveinsight.com/report-store/acral-lentiginous-melanoma-market
• Bronchial Spasms Market: https://www.delveinsight.com/report-store/bronchial-spasm-market
• Chronic Cutaneous Ulcer Market: https://www.delveinsight.com/report-store/chronic-cutaneous-ulcer-market
• Chronic Gout Market: https://www.delveinsight.com/report-store/chronic-gout-market
• Familial Primary Pulmonary Hypertension Market: https://www.delveinsight.com/report-store/familial-primary-pulmonary-hypertension-market
• Fibrocystic Breast Condition Market: https://www.delveinsight.com/report-store/fibrocystic-breast-condition-market
• Hpv-induced Cancers Market: https://www.delveinsight.com/report-store/hpv-induced-cancers-market
• Leber's Hereditary Optic Neuropathy Market: https://www.delveinsight.com/report-store/lebers-hereditary-optic-neuropathy-lhon-market
• Malt Lymphoma Market: https://www.delveinsight.com/report-store/malt-lymphoma-market
• Meningioma Market: https://www.delveinsight.com/report-store/meningioma-market
• Partial Seizure Market: https://www.delveinsight.com/report-store/partial-seizure-market
• Radiation Toxicity Market: https://www.delveinsight.com/report-store/radiation-toxicity-market
• Rhino Conjunctivitis Market: https://www.delveinsight.com/report-store/rhino-conjunctivitis-market

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Spinal Muscular Atrophy Pipeline Insight 2024, Therapies, Treatment and Companies: Analysis of Drugs, MOA, ROA, and Clinical Trials Results by DelveInsight here

News-ID: 3372889 • Views:

More Releases from DelveInsight Business Research

Spasticity Clinical Pipeline 2025: A Comprehensive Review of 12+ Emerging Therapies from 10+ key Players, says DelveInsight
Spasticity Clinical Pipeline 2025: A Comprehensive Review of 12+ Emerging Therap …
According to DelveInsight's latest analysis, the global Spasticity pipeline features more than 10 active pharmaceutical companies that are advancing over 12 investigational therapies. The report offers a detailed evaluation of clinical trials, mechanisms of action, therapeutic approaches, routes of administration, and major developmental activities shaping the Spasticity treatment landscape. DelveInsight's report, "Spasticity Pipeline Insight, 2025," delivers an extensive overview of the current clinical development environment and the future outlook for the
Real-World Evidence Solution Market is set to grow at a 8.07% CAGR, reaching USD 5.2 billion by 2032, analyses DelveInsight
Real-World Evidence Solution Market is set to grow at a 8.07% CAGR, reaching USD …
According to DelveInsight, the real-world evidence (RWE) solutions market is expanding rapidly, primarily due to the increasing global burden of chronic diseases and the growing need to improve healthcare outcomes. In addition, advancements in big data analytics, artificial intelligence, and machine learning are enhancing the ability to efficiently process and interpret large-scale real-world datasets. The rising adoption of RWE solutions by pharmaceutical and biotechnology companies - to support drug development,
Spinal Implants Market is set to grow at a 5.50% CAGR, reaching USD 21.9 billion by 2032, analyses DelveInsight
Spinal Implants Market is set to grow at a 5.50% CAGR, reaching USD 21.9 billion …
According to DelveInsight's assessment, the rising burden of spinal disorders particularly within the growing elderly population - continues to significantly increase the demand for surgical correction procedures. Alongside this, the surge in sports-related injuries and trauma cases is accelerating the need for advanced implantable spinal solutions. There is also a notable shift toward non-fusion and motion-preserving devices that support spinal flexibility and enhance patient outcomes, especially for younger and more
Vascular Stents Market is set to grow at a 6.65% CAGR, reaching USD 18.28 billion by 2032, analyses DelveInsight
Vascular Stents Market is set to grow at a 6.65% CAGR, reaching USD 18.28 billio …
According to DelveInsight's assessment, the rising global burden of cancer is significantly increasing the demand for advanced treatment approaches such as tumor ablation. Minimally invasive ablation techniques are gaining strong traction due to their advantages, including faster recovery times, lower complication risks, and reduced costs compared with traditional surgical procedures. At the same time, continuous improvements in ablation technologies - particularly in radiofrequency, microwave, and cryoablation systems - have enhanced

All 5 Releases


More Releases for Spinal

Evolving Market Trends In The Spinal Fusion Devices Industry: Advancements In Sp …
The Spinal Fusion Devices Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories]._x000D_ _x000D_ What Is the Expected Spinal Fusion Devices Market Size During the Forecast Period?_x000D_ Over the past few years, there has been a significant growth in the spinal fusion devices market. The market is projected
Key Influencer in the Spinal Fusion Devices Market 2025: Rising Spinal Disorder …
What Is the Forecasted Market Size and Growth Rate for the Spinal Fusion Devices Market? The market for spinal fusion devices has experienced significant growth in the past couple of years. Expectations are that it will rise from estimates of $7.85 billion in 2024 to approximately $8.31 billion in 2025, giving us a compound annual growth rate (CAGR) of 5.8%. Factors contributing to this notable expansion during the historical period can
Disposable Spinal Instrument Market: Revolutionizing Spinal Surgery with Hygiene …
Introduction The medical device market has witnessed a surge in demand for disposable instruments, especially in areas where hygiene, precision, and efficiency are paramount. One such sector experiencing rapid growth is the disposable spinal instrument market. Spinal surgeries, being intricate and requiring high precision, have traditionally relied on reusable instruments. However, growing concerns about hygiene, infection control, and surgical efficiency have accelerated the shift toward disposable spinal instruments. These devices not
Endoscopic Spinal Surgery Market: Minimally Invasive Solutions for Spinal Disord …
Global Endoscopic Spinal Surgery Market size was valued at US$ 667 Mn. in 2022 and the total revenue is expected to grow at a CAGR of 7.9% through 2022 to 2029, reaching nearly US$ 1137 Mn. Endoscopic Spinal Surgery Market Overview: Maximize Market Research is a research firm that has published a detailed analysis of the "Endoscopic Spinal Surgery Market". MMR in-depth market assessments in research reports consider significant technological advancements in
Spinal Resilience: Acute Spinal Cord Injury Drug Pipeline Landscape (2023)
Market Outlook: Charting Progress: Acute Spinal Cord Injury Drug Pipeline Landscape (2023) The Acute Spinal Cord Injury Drug Pipeline Landscape sets its sights on a decade of advancements poised to redefine the trajectory of spinal resilience. This comprehensive outlook explores the unfolding strategies, innovations, and breakthroughs that promise to revolutionize the landscape of acute spinal cord injury treatment. Market Drivers: Neuroregeneration on the Horizon: At the forefront of the Acute Spinal Cord Injury Drug
Spinal Laminoplasty Market - Revolutionizing spinal care with minimally invasive …
Newark, New Castle, USA: The "Spinal Laminoplasty Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors. Spinal Laminoplasty Market: https://www.growthplusreports.com/report/spinal-laminoplasty-market/8601 This latest report researches the industry structure, sales, revenue,